Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Hormone therapy shifts body proteins to match gender identity

Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...

Targeting 'molecular bodyguards' weakens prostate cancer cells

Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...

Females found to carry a higher genetic risk of depression

An international team of scientists has discovered about twice as many genetic 'flags'...

Content from other channels on our network

Keeping Infection Prevention Front of Mind – Every Day of the Year

WA invests $1.5bn in three major new public hospital projects

Framework seeks to cut medicine errors at transitions of care

Nominations open for 2026 HESTA Australian Nursing & Midwifery Awards

Report explores Australian perceptions of Medtech access

Discovery improves silicon solar efficiency

Partnership to redefine thermal comfort index

Dashboard to support climate-aware business decisions

Australia's homes aren’t ready for the heat — here's how to fix them

Program assists power station workers to find new careers

Coal mine land transfer 'a win‍-‍win outcome' for the Upper Hunter: BHP

Australia and Canada sign critical minerals agreement

UNSW scientists advance solar cell efficiency by splitting light

Aussie underwater robot company secures funding for expansion